GlassScriptPhysician profile
Angela N Smith
NPI 1740287838
$4,376.18
in general payments reported to CMS, 2019-2025
36 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $430 · 2021: $690 · 2022: $737 · 2023: $720 · 2024: $773 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.72 |
| Education | $245.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $701.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $509.86 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $509.76 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $428.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.55 | 2019-2024 | Jardiance |
| Pfizer INC. | $204.38 | 2019-2025 | |
| Exact Sciences Corporation | $193.72 | 2023-2025 | Cologuard Collection Kit |
| Nevro Corp. | $182.12 | 2022-2023 | Senza |
| Lilly USA, LLC | $156.93 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $134.21 | 2019-2024 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.42 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $108.16 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $103.15 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $73.59 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $69.41 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.61 | 2019-2024 | Welireg |
| Horizon Therapeutics Plc | $50.54 | 2021-2022 | |
| Evoke Pharma, INC. | $44.02 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $43.82 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $41.75 | 2021-2023 | Austedo |
| Sunovion Pharmaceuticals INC. | $40.25 | 2019-2022 | |
| Abiomed | $40.04 | 2024 | Impella |
| Daiichi Sankyo INC. | $37.96 | 2019-2020 | |
| Shield Therapeutics INC | $37.91 | 2023 | Accrufer |
| Ge Healthcare | $31.02 | 2019 | |
| Amgen INC. | $28.65 | 2019-2024 | Prolia, Evenity |
| Phathom Pharmaceuticals, INC. | $22.90 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $18.91 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $18.44 | 2025 | |
| Glaxosmithkline, LLC. | $18.24 | 2023 | Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $16.75 | 2021 | |
| Biogen, INC. | $16.39 | 2021 | |
| Allergan, INC. | $15.75 | 2021 | |
| Abbott Laboratories | $14.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.75 | 2021 | |
| Sanofi Pasteur INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.